CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2026 ($Million)

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Overview of Intravenous Immunoglobulin (IVIG)

3.2.1 Patented products

3.3 Epidemiology and economic burden of chronic conditions
3.4 Cost of side effects due to IVIG treatments
3.5 Key findings

3.5.1 Top Factors Impacting global intravenous immunoglobulin market
3.5.2 Top Investment pockets - Global Intravenous Immunoglobulin Market

3.6 Porter's five forces analysis

3.6.1 Bargaining power of buyers (Low)
3.6.2 Bargaining power of suppliers (Low)
3.6.3 Threat of new entrants (low)
3.6.4 Threat of substitutes (low)
3.6.5 Intense competitive rivalry (moderate)

3.7 Value chain analysis

3.7.1 Primary activities
3.7.2 Support Activities

3.8 Market share analysis (2014)
3.9 Product scenario in IVIG market
3.10 Government regulations and reimbursements

3.10.1 Intravenous Immunoglobulin (IVIG) regulations in United States and Europe
3.10.2 Reimbursements Scenario

3.11 Indications for IVIG

3.11.1 USFDA Indications
3.11.2 European Medicine Agency

3.12 Component analysis of intravenous immunoglobulins (IgG)

3.12.1 IgG1
3.12.2 IgG2
3.12.3 IgG3
3.12.4 IgG4

3.13 Clinical trials
3.14 Patent analysis of IVIG market (2011-2014)

3.14.1 Patent analysis by geography
3.14.2 U.S. patent analysis
3.14.3 Europe Patent Analysis

3.15 Market dynamics

3.15.1 Drivers

3.15.1.1 Rising Number of immunodeficieny Deficiency
3.15.1.2 Increase in adoption ofIVIG
3.15.1.3 Increasing Number of People with Bleeding Disorders
3.15.1.4 Rising Ageing Population

3.15.2 Restraints

3.15.2.1 Stringent Regulations
3.15.2.2 High Cost of Therapy

3.15.3 Opportunities

3.15.3.1 Opportunities in emerging economies
3.15.3.2 Development of cost effective therapeutics through large scale production

CHAPTER 4 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021

4.1 Hypogammaglobulinemia
4.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
4.1 Immunodeficiency diseases
4.2 Congenital AIDS
4.3 Chronic Lymphocytic Leukemia
4.4 Myasthenia Gravis
4.5 Multifocal motor neuropathy
4.6 Primary Immune thrombocytopenia (ITP)
4.7 Kawasaki disease
4.8 Guillain-Barre syndrome
4.9 Others

CHAPTER 5 GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET BY PRODUCT TYPES

5.1 IgG

5.1.1 Key Market Trends
5.1.2 Clinical Interpretations

5.2 IgA

5.2.1 Key Market Trends
5.2.2 Clinical interpretation

5.3 IgM

5.3.1 Key Market Trends
5.3.2 Clinical Interpretation

5.4 IgE

5.4.1 Key Market Trends
5.4.2 Clinical Interpretation

5.5 IgD

5.5.1 Key Market Trends

CHAPTER 6 GLOBAL IVIG MARKET, BY GEOGRAPHY, 2014-2021

6.1.1 Market size and forecast

6.2 North America

6.2.1 U.S.

6.2.1.1 Key Market Trends
6.2.1.2 Market size and forecast

6.2.2 Canada

6.2.2.1 Key Market Trends
6.2.2.2 Market size and forecast
6.2.2.3 Mexico
6.2.2.4 Key Market Trends
6.2.2.5 Market Size and forecast

6.3 Europe

6.3.1 Key market trends
6.3.2 Market size and forecast
6.3.3 U.K.

6.3.3.1 Key Market Trend
6.3.3.2 Market size and forecast

6.3.4 France

6.3.4.1 Key market trends
6.3.4.2 Market size and forecast

6.3.5 Germany

6.3.5.1 Market size and forecast

6.3.6 Italy

6.3.6.1 Market size and forecast

6.3.7 Austria

6.3.7.1 market size and forecast

6.3.8 Russia

6.3.8.1 market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends
6.4.2 Market size and forecast
6.4.3 Australia

6.4.3.1 Market size and forecast

6.4.4 Japan

6.4.4.1 Market size and forecast

6.4.5 India

6.4.5.1 Market size and forecast

6.4.6 China

6.4.6.1 Market size and forecast

6.4.7 Others

6.4.7.1 Market size and forecast

6.5 LAMEA

6.5.1 Key Market Trends
6.5.2 Market size and forecast
6.5.3 Latin America

6.5.3.1 Market size and forecast

6.5.4 Middle East

6.5.4.1 Market size and forecast

6.5.5 Africa

6.5.5.1 Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1 Biotest AG

7.1.1 Company overview
7.1.2 Biotest AG snapshot
7.1.3 Operating business segment overview
7.1.4 Financial performance
7.1.5 Strategic moves and developments
7.1.6 SWOT analysis of Biotest AG

7.2 Octapharma AG

7.2.1 Company overview
7.2.2 Octapharma AG snapshot
7.2.3 Operating business segment overview
7.2.4 Strategic moves and developments
7.2.5 SWOT analysis of Octapharma AG

7.3 Baxter International Inc.

7.3.1 Company overview
7.3.2 Baxter International Inc. snapshot
7.3.3 Operating business segments overview
7.3.4 Financial performance
7.3.5 Strategic moves and developments
7.3.6 SWOT analysis of Baxter International Inc.

7.4 LFB Biotechnologies

7.4.1 Company overview
7.4.2 LFB Biotechnologies snapshot
7.4.3 Operating business segment overview
7.4.4 Financial performance
7.4.5 SWOT analysis of LFB biotechnologies

7.5 China Biologics Products Inc.

7.5.1 Company overview
7.5.2 China Biologic Products Inc. Snapshot
7.5.3 Operating business segment overview
7.5.4 Financial performance
7.5.5 Strategic moves and developments
7.5.6 SWOT analysis of China Biologic Products Inc.

7.6 Grifols S.A.

7.6.1 Company overview
7.6.2 Grifols S.A Snapshot
7.6.3 Operating Business Segment Overview
7.6.4 Financial performance
7.6.5 Strategic moves and developments
7.6.6 SWOT analysis Grifols S.A.

7.7 Kedrion Biopharma

7.7.1 Company overview
7.7.2 Kedrion Biopharma. Snapshot
7.7.3 Operating business segment overview
7.7.4 Financial performance
7.7.5 Strategic moves and developments
7.7.6 SWOT Analysis of Kedrion Biopharma.

7.8 CSL Behring

7.8.1 Company overview
7.8.2 CSL Behring Snapshot
7.8.3 Operating business segment overview
7.8.4 Financial performance
7.8.5 Strategic moves and developments
7.8.6 SWOT ANALYSIS of CSL Behring

7.9 BDI Pharma Inc.

7.9.1 Company overview
7.9.2 BDI pharma Inc. Snapshot
7.9.3 Operating business segment overview
7.9.4 SWOT Analysis of BDI Pharma

7.10 Bayer Healthcare

7.10.1 Company overview
7.10.2 Business performance
7.10.3 Strategic moves and developments
7.10.4 SWOT analysis of Bayer Healthcare